1. Synthesis of 2,2-dimethyl-chroman-based stereochemically flexible and constrained anti-breast cancer agents.
- Author
-
Nainawat KS, Gupta K, Gupta N, Singh R, Mishra D, Nirwan A, Verma M, Singh A, Vasudev PG, Khan F, Mishra DP, and Gupta A
- Subjects
- Humans, Stereoisomerism, Structure-Activity Relationship, Cell Line, Tumor, Chromans pharmacology, Chromans chemical synthesis, Chromans chemistry, Molecular Docking Simulation, Estrogen Receptor alpha metabolism, Estrogen Receptor alpha antagonists & inhibitors, Female, Molecular Structure, MCF-7 Cells, Dose-Response Relationship, Drug, Tamoxifen pharmacology, Tamoxifen chemical synthesis, Tamoxifen chemistry, Antineoplastic Agents pharmacology, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Cell Proliferation drug effects, Drug Screening Assays, Antitumor, Apoptosis drug effects
- Abstract
Receptors are proteinous macromolecules which remain in the apo form under normal/unliganded conditions. As the ligand approaches, there are specific stereo-chemical changes in the apo form of the receptor as per the stereochemistry of a ligand. Accordingly, a series of substituted dimethyl-chroman-based stereochemically flexible and constrained Tamoxifen analogs were synthesized as anti-breast cancer agents. The synthesized compounds 19a-e, 20a-e, 21, and 22a-e, showed significant antiproliferative activity against estrogen receptor-positive (ER
+ , MCF-7) and negative (ER- , MDA MB-231) cells within IC50 value 8.5-25.0 µM. Amongst all, four potential molecules viz 19b, 19e, 22a, and 22c, were evaluated for their effect on the cell division cycle and apoptosis of ER+ and ER- cancer cells (MCF-7 & MDA MB-231cells), which showed that these compounds possessed antiproliferative activity through triggering apoptosis. In-silico docking experiments elucidated the possible affinity of compounds with estrogen receptors-α and -β., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF